$19.24
Value $669M
DCTH and JNJ stock compared: price, dividend, valuation and results, from SEC filings.
$19.24
Value $669M
$267.14
Value $644B
Delcath Systems (DCTH) has a market value of $669M and Johnson & Johnson (JNJ) $644B. Over the last year, with dividends, DCTH moved +128.8% and JNJ +39.7%. The P/E is 100.5 for DCTH and 40.0 for JNJ. Dividend yield: DCTH none, JNJ 1.98%.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
DCTH$669M
JNJ$644B
JNJ is 963 times DCTH
Revenue, 12 months
DCTH$110M
JNJ$99.3B
JNJ is 903 times DCTH
Net income, 12 months
DCTH$6.7M
JNJ$16.1B
JNJ is 2,419 times DCTH
Operating margin
DCTH5.2%
JNJ–
ROIC
DCTH3.6%
JNJ12.4%
8.8 points apart
P/E
DCTH100.5
JNJ40.0
DCTH is 2.5 times JNJ
Dividend yield
DCTH0.0%
JNJ2.0%
2.0 points apart
5-year return
DCTH+97.2%
JNJ+92.0%
5.2 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
DCTH+96.2%
JNJ+92.0%
| Period | DCTHWith dividends | JNJWith dividends |
|---|---|---|
| 1 year since November 17, 2025 | +128.8%Price +128.8% | +39.7%Price +36.6% |
| 3 years since November 17, 2023 | +704.1%+100.3% a yearPrice +704.1% | +98.2%+25.6% a yearPrice +82.1% |
| 5 years since November 17, 2021 | +97.2%+14.5% a yearPrice +97.2% | +92.0%+13.9% a yearPrice +67.0% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
DCTHDelcath SystemsJNJJohnson & Johnson
| Price | $19.24 | $267.14 |
|---|---|---|
| Market value | $669M | $644B |
| Enterprise value (EV) | $564M | $671B |
| P/E | 100.5 | 40.0 |
| P/E, 5-year median | – | 21.9 |
| P/B | 5.0 | 7.9 |
| EV/EBIT | 99.2 | 37.8 |
| Free cash flow yield | 3.0% | 3.2% |
| Revenue, 12 months | $110M | $99.3B |
|---|---|---|
| Net income, 12 months | $6.7M | $16.1B |
| Free cash flow, 12 months | $20M | $20.6B |
| Earnings per share, 12 months | $0.19 | $6.59 |
| Revenue growth, year on year | 129.1% | 6.1% |
| Revenue growth a year, past | +121.3%over 4 years | +2.7%over 5 years |
| EPS growth a year, past | – | +14.9%over 5 years |
| Gross margin | 87.6% | 67.6% |
|---|---|---|
| Operating margin | 5.2% | – |
| Net margin | 6.1% | 16.2% |
| ROIC | 3.6% | 12.4% |
| ROE | 5.6% | 19.7% |
| Cash | $104M | $17.2B |
|---|---|---|
| Total debt | $2.4M | $44.7B |
| Net debt / EBITDA | -17.6 | 1.1 |
| Interest cover | – | 18.0× |
| Dividend yield | – | 2.0% |
|---|---|---|
| Dividend per share, 12 months | – | $5.28 |
| Dividend growth a year, past | – | +5.3%over 5 years |
| Buyback yield | 0.9% | 0.9% |
| Shareholder yield | 0.9% | 2.9% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, Johnson & Johnson ($644B) is about 963.0 times Delcath Systems ($669M), at today's prices.
Since November 17, 2021, DCTH's price moved +97.2% and JNJ's +67.0%. With dividends: DCTH +97.2% (+14.5% a year), JNJ +92.0% (+13.9% a year). Past returns do not predict future ones.
The dividend yield at today's price is none for Delcath Systems and 1.98% for Johnson & Johnson. Over the last twelve months they paid – and $5.28 per share.
At today's price, the P/E is 100.5 for DCTH and 40.0 for JNJ. It is the share price over the last twelve months' earnings per share.
Over the last twelve months, the net margin was 6.1% for Delcath Systems and 16.2% for Johnson & Johnson, and the operating margin 5.2% and –. Revenue was $110M and $99.3B.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.